Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(625)
•••
Comment by KayakerBCon Jul 23, 2016 12:02pm
161 Views
Post# 25078422

RE:RE:RE:RE:New CEO Blog: Why biOasis Matters

RE:RE:RE:RE:New CEO Blog: Why biOasis Matters
Jekyl Jr. Pretty laughable watching you critique other people's predictions.  Have you no shame?

In June you said, that nothing would happen this year, that BTI would not have any meaningful stock moves without clinical data, that no one is sold on the technology, and that the stock price at the end of the year would be where it is now.

You on June 28th...

"If we had the data to get a "money deal" then this would not be priced where it is. I'm not sure why you are having a difficult time grasping this. I guess you can only lead a horse to the water and not push its head in it. "

Morning of July 20th you said...

"The only ones that have and will make money on this are the ones employeed by the organization."

And then, afternoon of July 20th, contradicting all of that, you said....

"The volume is about to come back
Look at the low of the day today. We will never see that again. This will run hard into a deal by end of this month."
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities